Precision BioSearch is pleased to have partnered with Oxford Science Enterprises during the launch phase of Alethiomics to secure Dr Edward Ainscow as CSO. Edward joins as the first employee of the new spin-out company, financed with £6M seed funding from OSE. He brings over two decades of experience in innovative drug discovery from both Biotech and Pharma.
Regarding working with Precision BioSearch, Uciane Scarlett, Investment Principal at OSE, commented: “I respect and admire Jemma’s experience within the European biotech industry for identifying and engaging top talent. I used Precision for several successful searches in 2021, including … Alethiomics. It was a pleasure working with her and her team. Her approach, professionalism, and dedication made the process quick and efficient. I would recommend Jemma as a partner in finding top-tier talent.”
About Alethiomics: Spun out of the University of Oxford in December 2021, Alethiomics is a drug discovery company using pioneering single-cell multi-omic approaches to identify novel drug targets within the mutants cells present in myeloproliferative neoplasms (MPNs), a group of blood cancers. Alethiomics will develop therapeutics against the new molecular targets to provide advanced treatment options which tackle the underlying drivers of disease to improve patient outcomes.
For more information, visit: www.alethiomics.com
Posted on : 15th December 2021